SARTF (Sartorius AG) Long-Term Debt: $3,663 Mil (As of Mar. 2026)


SARTF Sartorius AG SARTF
85 GF Score
Price $212.80
GF Value $234.29
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Sartorius AG Long-Term Debt?

Sartorius AG SARTF 85 Long-Term Debt is $3,663 Mil as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $234.29 (Fairly Valued). The stock has 9 warning signs investors should review.

Sartorius AG's Long-Term Debt for the quarter that ended in Mar. 2026 was $3,663 Mil.

Sartorius AG's quarterly Long-Term Debt declined from Sep. 2025 ($3,799 Mil) to Dec. 2025 ($3,729 Mil) and declined from Dec. 2025 ($3,729 Mil) to Mar. 2026 ($3,663 Mil).

Sartorius AG's annual Long-Term Debt declined from Dec. 2023 ($5,354 Mil) to Dec. 2024 ($4,212 Mil) and declined from Dec. 2024 ($4,212 Mil) to Dec. 2025 ($3,729 Mil).

Sartorius AG  (OTCPK:SARTF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sartorius AG Long-Term Debt Related Terms

Sartorius AG Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Long-Term Debt Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,863.39 1,984.96 5,353.65 4,211.62 3,728.69

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,343.46 4,514.53 3,799.41 3,728.69 3,663.35
SARTF
85GF Score
Sartorius AG SARTF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $3,663 Mil mean?
Sartorius AG (SARTF) has a Long-Term Debt of $3,663 Mil as of Mar. 2026.
Is Sartorius AG's Long-Term Debt too high?
Sartorius AG's current Long-Term Debt is $3,663 Mil. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Long-Term Debt compare to ISRG and BDX?
Sartorius AG's Long-Term Debt of $3,663 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sartorius AG's current Long-Term Debt is $3,663 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $234.29, compared to a current price of $212.80 — trading 9.2% below its estimated fair value. The current Long-Term Debt is $3,663 Mil. Sartorius AG's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Long-Term Debt is $3,663 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $212.80 is trading 9.2% below its estimated GF Value™ of $234.29. GuruFocus considers Sartorius AG to be Fairly Valued.

Key valuation signals for SARTF:

  • Long-Term Debt: $3,663 Mil
  • GF Value™: $234.29 vs. price of $212.80 (9.2% below fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score

Get the complete analysis for SARTF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$212.80
Price
$234.29
GF Value